Informe completo: Stereotactic ablative radiotherapy to treat people with primary kidney cancer

Resumen: Stereotactic ablative radiotherapy (SABR) for renal cell carcinoma (RCC)

Objetivo: Identify and summarize evidence addressing the following review question: what is the clinical and cost effectiveness of stereotactic ablative radiotherapy (SABR) for primary kidney cancer compared to standard care?

Autoría: Health Technology Wales (HTW)

Idioma: inglés

Fuente: INAHTA

Año de publicación: 2022